Cargando…

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls

The tight regulation of sleep/wake states is critical for mental and physiological wellbeing. For example, dysregulation of sleep/wake systems predisposes individuals to metabolic disorders such as obesity and psychiatric problems, including depression. Contributing to this understanding, the last d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeoh, Jiann Wei, Campbell, Erin J., James, Morgan H., Graham, Brett A., Dayas, Christopher V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934415/ https://www.ncbi.nlm.nih.gov/pubmed/24616658 http://dx.doi.org/10.3389/fnins.2014.00036

Ejemplares similares

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

Opportunities and perspectives for developing orexin receptor antagonists
por: Steiner, Michel A., et al.
Publicado: (2014)

Electrophysiological characteristics of paraventricular thalamic (PVT) neurons in response to cocaine and cocaine- and amphetamine-regulated transcript (CART)
por: Yeoh, Jiann Wei, et al.
Publicado: (2014)

Orexin receptor antagonists as therapeutic agents for insomnia
por: Equihua, Ana C., et al.
Publicado: (2013)

Kinetic properties of “dual” orexin receptor antagonists at OX(1)R and OX(2)R orexin receptors
por: Callander, Gabrielle E., et al.
Publicado: (2013)

Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models
por: Anderson, Rachel I., et al.
Publicado: (2014)

Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use
por: Merlo Pich, Emilio, et al.
Publicado: (2014)

The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats
por: Morairty, Stephen R., et al.
Publicado: (2014)

Exercise reverses the effects of early life stress on orexin cell reactivity in male but not female rats
por: James, Morgan H., et al.
Publicado: (2014)

LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy
por: Fitch, Thomas E., et al.
Publicado: (2014)

Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis
por: Xue, Tao, et al.
Publicado: (2023)

Recruitment of hypothalamic orexin neurons after formalin injections in adult male rats exposed to a neonatal immune challenge
por: Campbell, Erin J., et al.
Publicado: (2015)

Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism
por: Dugovic, Christine, et al.
Publicado: (2014)

Orexin A and orexin receptor 1 axonal traffic in dorsal roots at the CNS/PNS interface
por: Colas, Damien, et al.
Publicado: (2014)

The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome
por: Steiner, Michel A., et al.
Publicado: (2013)

Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats
por: Illenberger, Jessica M., et al.
Publicado: (2023)

Orexin, cardio-respiratory function, and hypertension
por: Li, Aihua, et al.
Publicado: (2014)

Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice
por: Etori, Keishi, et al.
Publicado: (2014)

Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators
por: Ramirez, Andres D., et al.
Publicado: (2013)

Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation
por: Bonaventure, Pascal, et al.
Publicado: (2017)

Hypocretin (orexin) regulation of sleep-to-wake transitions
por: de Lecea, Luis, et al.
Publicado: (2014)

Multiomics integration reveals the effect of Orexin A on glioblastoma
por: Yang, Sha, et al.
Publicado: (2023)

An Emerging Role for the Mammalian Target of Rapamycin in “Pathological” Protein Translation: Relevance to Cocaine Addiction
por: Dayas, Christopher V., et al.
Publicado: (2012)

OX(1) and OX(2) orexin/hypocretin receptor pharmacogenetics
por: Thompson, Miles D., et al.
Publicado: (2014)

Daily Fluctuation of Orexin Neuron Activity and Wiring: The Challenge of “Chronoconnectivity”
por: Azeez, Idris A., et al.
Publicado: (2018)

Modulation of sleep behavior in zebrafish larvae by pharmacological targeting of the orexin receptor
por: Pardon, Marie, et al.
Publicado: (2022)

What evidence is there for implicating the brain orexin system in neuropsychiatric symptoms in dementia?
por: Bergamini, Giorgio, et al.
Publicado: (2022)

Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update
por: Asgharian, Parina, et al.
Publicado: (2022)

Cocaine- and Amphetamine-Regulated Transcript (CART) Signaling within the Paraventricular Thalamus Modulates Cocaine-Seeking Behaviour
por: James, Morgan H., et al.
Publicado: (2010)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Pharmacological or genetic orexin1 receptor inhibition attenuates MK-801 induced glutamate release in mouse cortex
por: Aluisio, Leah, et al.
Publicado: (2014)

Sphingosine-1-Phosphate Receptor-2 Antagonists: Therapeutic Potential and Potential Risks
por: Blankenbach, Kira V., et al.
Publicado: (2016)

Synthesis and biological activity evaluation of azacycloheptane sulfonamide derivatives as potential orexin receptor antagonists
por: Guo, Bin, et al.
Publicado: (2020)

Differential actions of orexin receptors in brainstem cholinergic and monoaminergic neurons revealed by receptor knockouts: implications for orexinergic signaling in arousal and narcolepsy
por: Kohlmeier, Kristi A., et al.
Publicado: (2013)

Neuropsychiatric Disorders in Chronic Kidney Disease
por: Simões e Silva, Ana Cristina, et al.
Publicado: (2019)

Intranasal neuropeptide Y is most effective in some aspects of acute stress compared to melatonin, oxytocin and orexin
por: Zubkov, Eugene, et al.
Publicado: (2022)

Targeting the chemerin/CMKLR1 axis by small molecule antagonist α-NETA mitigates endometriosis progression
por: Yu, Ming, et al.
Publicado: (2022)

The role of maternal obesity in the risk of neuropsychiatric disorders
por: Rivera, Heidi M., et al.
Publicado: (2015)

Potential Clinical Implications of the Urotensin II Receptor Antagonists
por: Tsoukas, Philip, et al.
Publicado: (2011)

Hepcidin antagonists for potential treatments of disorders with hepcidin excess
por: Poli, Maura, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_prvfkff1ig5lkfe5c88hr72q5n